All In Biotech

Drug Trial Radar · NCT02055638

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

97

Actual

Start

May 2014

Primary completion

May 2016

Study completion May 2016

Sponsor

Lead sponsor
Azevan PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED). Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will be randomized to either SRX246 or Placebo treatment groups. Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits throughout the trial. The study results will be determined based on any changes observed over the study period.

Conditions

  • Intermittent Explosive Disorder

Interventions

  • SRX246Drug

    capsules

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: from initial dose of intervention until completion of the study up to 8 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • University of Chicago, Department of Psychiatry

    Chicago, Illinois

  • Psychiatric Care and Research Center

    O'Fallon, Missouri

  • SPRI Clinical Trials, LLC

    Brooklyn, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Lindner Center of HOPE

    Mason, Ohio

  • Rhode Island Hospital, Department of Psychiatry

    Providence, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.